Aradigm (NASDAQ:ARDM) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Monday.
According to Zacks, “Aradigm Corp. is a leading developer of advanced pulmonary drug delivery systems for the treatment of systemic conditions as well as lung diseases. Their hand-held AERx platform is being designed for the rapid and reproducible delivery of a wide range of pharmaceutical drugs and biotech compounds via the lung. “
Several other research firms have also commented on ARDM. ValuEngine upgraded shares of Aradigm from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Ladenburg Thalmann Financial Services lowered shares of Aradigm from a “buy” rating to a “neutral” rating in a research report on Friday, January 12th.
Shares of Aradigm stock opened at $1.25 on Monday. The company has a market cap of $20.63, a P/E ratio of -1.28 and a beta of 0.99. Aradigm has a 1 year low of $0.78 and a 1 year high of $7.35. The company has a debt-to-equity ratio of -1.59, a current ratio of 1.65 and a quick ratio of 1.65.
In related news, insider Juergen Kurt Froehlich sold 17,011 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $1.53, for a total transaction of $26,026.83. Following the transaction, the insider now owns 90,853 shares of the company’s stock, valued at $139,005.09. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 7.30% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in ARDM. Jane Street Group LLC purchased a new position in shares of Aradigm during the third quarter valued at approximately $122,000. Eversept Partners LLC purchased a new position in Aradigm during the fourth quarter worth approximately $349,000. Finally, Geode Capital Management LLC purchased a new position in Aradigm during the fourth quarter worth approximately $422,000. 36.88% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Aradigm (ARDM) Lifted to “Hold” at Zacks Investment Research” was published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.thestockobserver.com/2018/03/21/aradigm-ardm-lifted-to-hold-at-zacks-investment-research.html.
Aradigm Company Profile
Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aradigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm and related companies with MarketBeat.com's FREE daily email newsletter.